Status: Not yet recruiting
Pharmacokinetic and Safety Study of Metronidazole Oral Suspension in Pediatric Patients With Anaerobic Bacterial Infection
This is an open-label, single-arm, pharmacokinetic and safety study of Likmez® in pediatric patients aged 12 months to \<4 years with anaerobic bacterial infection
Participants needed: 30
Trial details
Phase: Phase 2Age: 12-4Biological sex: AllType: InterventionalSponsor: Saptalis Pharmaceuticals LLCUpdated: Aug 28, 2025Locations: 3
Eligibility criteria
Age between ≥ 12 months and < 4 years till the time of dosing in the study [+9]
History of anaphylactic reaction to metronidazole or other nitroimidazole deriva... [+20]